Zevra Therapeutics (NASDAQ:ZVRA) PT Raised to $20.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target lifted by equities researchers at HC Wainwright from $18.00 to $20.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 148.14% from the company’s current price.

Several other analysts have also recently issued reports on ZVRA. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average price target of $21.25.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.06 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $8.95. The company has a fifty day simple moving average of $7.04 and a 200-day simple moving average of $5.71. The firm has a market capitalization of $337.34 million, a price-to-earnings ratio of -5.97 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period in the previous year, the company earned ($0.15) EPS. On average, equities analysts anticipate that Zevra Therapeutics will post -1.58 EPS for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the stock in a transaction dated Friday, July 12th. The shares were acquired at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the completion of the transaction, the director now owns 30,000 shares in the company, valued at approximately $176,100. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have purchased 22,000 shares of company stock worth $140,340 over the last three months. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics during the 1st quarter worth $64,000. The Manufacturers Life Insurance Company raised its stake in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares during the last quarter. Focus Financial Network Inc. ADV acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth $141,000. Virtu Financial LLC purchased a new stake in Zevra Therapeutics during the 4th quarter worth about $177,000. Finally, Jacobs Levy Equity Management Inc. increased its position in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.